What are keytruda's flexible dosing options?

Keytruda (pembrolizumab) offers a few flexible dosing schedules that are used depending on the cancer type and regulatory approval. The main options are:

- 200 mg IV every 3 weeks (Q3W) — fixed-dose, common across many indications.
- 400 mg IV every 6 weeks (Q6W) — fixed-dose, extended-interval option that achieves the same total exposure as the Q3W dose.
- 2 mg/kg IV every 3 weeks (Q3W) — weight-based dosing; used in some settings or when a fixed dose isn’t preferred.

Notes:
- The exact regimen depends on the specific cancer, prior therapy, and country/label approval. Your clinician will choose the appropriate schedule.
- Infusion typically lasts about 30 minutes (longer if needed for reactions).
- Dosing may be adjusted or switched between regimens under a clinician’s guidance (for example, moving from Q3W to Q6W).

If you have a particular indication in mind (e.g., melanoma, NSCLC, RCC, etc.), I can give more precise dosing options from that label.